HK1052500A1 - Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase - Google Patents

Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase

Info

Publication number
HK1052500A1
HK1052500A1 HK03103231A HK03103231A HK1052500A1 HK 1052500 A1 HK1052500 A1 HK 1052500A1 HK 03103231 A HK03103231 A HK 03103231A HK 03103231 A HK03103231 A HK 03103231A HK 1052500 A1 HK1052500 A1 HK 1052500A1
Authority
HK
Hong Kong
Prior art keywords
pyridine derivatives
tyrosine kinase
receptor tyrosine
vegf receptor
inhibiting angiogenesis
Prior art date
Application number
HK03103231A
Other languages
English (en)
Inventor
Guido Bold
Paul William Manley
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1052500A1 publication Critical patent/HK1052500A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK03103231A 2000-02-09 2003-05-06 Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase HK1052500A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH2652000 2000-02-09
PCT/EP2001/001331 WO2001058899A1 (en) 2000-02-09 2001-02-07 Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase

Publications (1)

Publication Number Publication Date
HK1052500A1 true HK1052500A1 (en) 2003-09-19

Family

ID=4475612

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03103231A HK1052500A1 (en) 2000-02-09 2003-05-06 Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase

Country Status (10)

Country Link
US (2) US6706731B2 (de)
EP (1) EP1254138B1 (de)
JP (1) JP4837864B2 (de)
AT (1) ATE295365T1 (de)
AU (1) AU2001231710A1 (de)
DE (1) DE60110749T2 (de)
ES (1) ES2241781T3 (de)
HK (1) HK1052500A1 (de)
PT (1) PT1254138E (de)
WO (1) WO2001058899A1 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2000000070A (es) * 1999-09-28 2002-02-28 Bayer Healthcare Llc Piridinas y piridacinas sustituidas con actividad de inhibición de angiogénesis
JP4837864B2 (ja) * 2000-02-09 2011-12-14 ノバルティス アーゲー 血管形成および／またはｖｅｇｆ受容体チロシンキナーゼを阻害するピリジン誘導体
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
DE60324416D1 (de) * 2002-05-16 2008-12-11 Novartis Ag Verwendung von edg rezeptor bindenden wirkstoffen für die krebstherapie
AU2003270701B2 (en) 2002-10-31 2009-11-12 Amgen Inc. Antiinflammation agents
ES2318276T3 (es) * 2003-03-11 2009-05-01 Novartis Ag Uso de los derivados de la isoquinolina para tratar el cancer y las enfermedades relacionadas con la quinasa map.
US7592466B2 (en) 2003-10-09 2009-09-22 Abbott Laboratories Ureas having antiangiogenic activity
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
TW200606129A (en) * 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
AU2008226844A1 (en) * 2007-03-13 2008-09-18 Merck Sharp & Dohme Corp. Inhibitors of janus kinases and/or 3-phosphoinositide-dependent protein kinase-1
CA2684965A1 (en) * 2007-04-23 2008-10-30 Novartis Ag Phthalazine and isoquinoline derivatives with s1p receptor modulating activities
JP2011526892A (ja) 2008-06-30 2011-10-20 アンジオブラスト システムズ，インコーポレーテッド 併用療法を使用した眼疾患及び過剰血管新生の治療
NZ591820A (en) 2008-08-27 2012-12-21 Leo Pharma As Pyridine derivatives as vegfr-2 receptor and protein tyrosine kinase inhibitors
EP2336105B9 (de) 2008-09-19 2014-09-17 Takeda Pharmaceutical Company Limited Stickstoffhaltige heterozyklische verbindung und ihre verwendung
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
IN2012DN02139A (de) 2009-09-10 2015-08-07 Novartis Ag
WO2011064211A1 (en) 2009-11-25 2011-06-03 Novartis Ag Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
WO2011157793A1 (en) 2010-06-17 2011-12-22 Novartis Ag Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
CN102947274A (zh) 2010-06-17 2013-02-27 诺瓦提斯公司 联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
CN103492390A (zh) 2011-03-08 2014-01-01 诺瓦提斯公司 氟苯基双环杂芳基化合物
ME02651B (de) 2012-06-13 2017-06-20 Incyte Holdings Corp Substituierte tricyclische verbindungen als fgfr-inhibitoren
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CA2909207C (en) 2013-04-19 2021-11-02 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CR20170390A (es) 2015-02-20 2017-10-23 Incyte Holdings Corp Heterociclos biciclicos como inhibidores de fgfr
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
EP3414330A4 (de) 2016-02-08 2019-07-03 Vitrisa Therapeutics, Inc. Zusammensetzungen mit verbesserter intravitrealer halbwertzeit und verwendungen dafür
JP7144863B2 (ja) 2016-12-28 2022-09-30 ミノリックス セラピューティクス エセ．エレ． イソキノリン化合物、その調製の方法、およびベータガラクトシダーゼの活性の変質に伴う状態におけるその治療的使用
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US12023353B2 (en) 2017-10-18 2024-07-02 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Methods and compounds for improved immune cell therapy
JP7021356B2 (ja) 2017-12-21 2022-02-16 ヘフェイ インスティテューツ オブ フィジカル サイエンス， チャイニーズ アカデミー オブ サイエンシーズ ピリミジン誘導体系キナーゼ阻害剤類
BR112020022373A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation sais de um inibidor de fgfr
WO2019213544A2 (en) 2018-05-04 2019-11-07 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
CA3104808A1 (en) * 2018-07-02 2020-01-09 Ecole Polytechnique Federale De Lausanne (Epfl) Lactate enhancing compounds and uses thereof
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JOP20220083A1 (ar) 2019-10-14 2023-01-30 Incyte Corp حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US20220395553A1 (en) 2019-11-14 2022-12-15 Cohbar, Inc. Cxcr4 antagonist peptides
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
PE20231739A1 (es) 2020-07-02 2023-10-31 Incyte Corp Compuestos triciclicos de urea como inhibidores de jak2 v617f
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
US11958861B2 (en) 2021-02-25 2024-04-16 Incyte Corporation Spirocyclic lactams as JAK2 V617F inhibitors
TW202313611A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE792648A (fr) * 1971-12-13 1973-06-12 May & Baker Ltd Derives de l'isoquinoleine
JPS58164577A (ja) * 1982-03-24 1983-09-29 Taiho Yakuhin Kogyo Kk ４―ベンジル―１―（２ｈ）イソキノロン誘導体
US4405790A (en) * 1982-04-08 1983-09-20 Reilly Tar & Chemical Corp. Process for preparing 2-alkylamino- and 2-amino-5-alkylpyridines
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
WO1997034876A1 (en) * 1996-03-15 1997-09-25 Zeneca Limited Cinnoline derivatives and use as medicine
US6809097B1 (en) * 1996-09-25 2004-10-26 Zeneca Limited Quinoline derivatives inhibiting the effect of growth factors such as VEGF
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
JP4516690B2 (ja) * 1998-08-11 2010-08-04 ノバルティス アーゲー 血管形成阻害活性を有するイソキノリン誘導体
JP4837864B2 (ja) * 2000-02-09 2011-12-14 ノバルティス アーゲー 血管形成および／またはｖｅｇｆ受容体チロシンキナーゼを阻害するピリジン誘導体

Also Published As

Publication number Publication date
US6706731B2 (en) 2004-03-16
PT1254138E (pt) 2005-09-30
EP1254138A1 (de) 2002-11-06
DE60110749T2 (de) 2006-02-02
EP1254138B1 (de) 2005-05-11
US20040209894A1 (en) 2004-10-21
AU2001231710A1 (en) 2001-08-20
ATE295365T1 (de) 2005-05-15
DE60110749D1 (de) 2005-06-16
JP2003522773A (ja) 2003-07-29
WO2001058899A1 (en) 2001-08-16
JP4837864B2 (ja) 2011-12-14
US20030158409A1 (en) 2003-08-21
ES2241781T3 (es) 2005-11-01
US7323474B2 (en) 2008-01-29

Similar Documents

Publication Publication Date Title
HK1052500A1 (en) Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
MXPA03010207A (es) Nuevas 4-anilinoquinolin-3-carboxamidas.
MXPA02011320A (es) Derivados de pirazol triciclico como inhibidores de cinasa.
WO2002015662A3 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
WO2002017358A3 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
WO2006011050A3 (en) Pyridine derivatives
AU3652102A (en) Compounds and their uses
HUP0204083A3 (en) 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
GB0114286D0 (en) Nucleoside Derivatives
WO2002048147A3 (en) Pyrazolopyridines
JO2372B1 (en) Source drugs of 4-phenylpyridine derivatives
NO20060415L (no) Piperidyl-Kinazolinderivater som Tyrosin-Kinase-Inhibitorer
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
AU6011301A (en) 1,2,3,4-tetrahydroisoquinoline derivatives
MX2007010414A (es) Derivados de piridin-2-carboxamida como antagonistas de mglur5.
MY138851A (en) Quinazoline derivatives
ES2243579T3 (es) Derivados de pirazolopirideno.
MY129668A (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
MY128241A (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
IL151200A0 (en) Tricyclic imidazopyridine prodrug derivatives and pharmaceutical compositions containing the same
WO2002014281A8 (en) Pyridine derivatives as inhibitors of p38
BG105731A (en) 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives
IL159554A0 (en) Tricyclic imidazopyridine derivatives and pharmaceutical compositions containing the same
WO2005030209A8 (en) Pyridine derivatives and use thereof as urotensin ii antagonists

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100207